Compare McCormick & Company, Incorporated (MKC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Travere Therapeutics Inc. Common Stock — how do they compare? McCormick & Company, Incorporated trades at $44.93 (market cap $12.02B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: McCormick & Company, Incorporated is far larger — about 2.5× Travere Therapeutics Inc. Common Stock's market cap, and McCormick & Company, Incorporated pays a 4.3% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 68 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MKC | TVTX | |
|---|---|---|
Market Cap | $12.02B | $4.88B |
Volume | 3,822,006 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $67.52 |
52-Week Low | $44.14 | $26.79 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $16.71B | $5.01B |
Dividend Yield | 4.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $44.80, down 1.71% on the day, with a bearish technical signal from moving averages. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Valuation ratios appear attractive with a P/E of 8.07 and net income margin of 19.39%. Recent news highlights the acquisition of McCormick de Mexico and a reaffirmed 2026 outlook.
The stock offers value with solid profitability and dividend growth, but faces near-term technical headwinds and mixed analyst sentiment. Upside exists toward the $53.50 consensus target, though execution risks and market volatility require monitoring. The current price near support at $44 suggests a potential entry point for long-term investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
